Geratherm Medical Future Growth
Future criteria checks 3/6
Geratherm Medical is forecast to grow earnings and revenue by 89.5% and 1.9% per annum respectively. EPS is expected to grow by 92.8% per annum. Return on equity is forecast to be 1.8% in 3 years.
Key information
89.5%
Earnings growth rate
92.8%
EPS growth rate
| Medical Equipment earnings growth | 14.1% |
| Revenue growth rate | 1.9% |
| Future return on equity | 1.8% |
| Analyst coverage | Low |
| Last updated | 11 Nov 2024 |
Recent future growth updates
Recent updates
Geratherm Medical AG (ETR:GME) Stock Catapults 28% Though Its Price And Business Still Lag The Industry
Dec 13
Investors Don't See Light At End Of Geratherm Medical AG's (ETR:GME) Tunnel And Push Stock Down 26%
Oct 16The Market Lifts Geratherm Medical AG (ETR:GME) Shares 28% But It Can Do More
Aug 21We Think Geratherm Medical's (ETR:GME) Solid Earnings Are Understated
Jun 27Geratherm Medical (ETR:GME) Is Reducing Its Dividend To €0.12
Apr 10Is Geratherm Medical (ETR:GME) A Risky Investment?
Mar 02Geratherm Medical (ETR:GME) Has Some Way To Go To Become A Multi-Bagger
May 08Is Geratherm Medical AG's (ETR:GME) 2.1% Dividend Sustainable?
Apr 19Is Geratherm Medical (ETR:GME) A Risky Investment?
Mar 01Returns On Capital Tell Us A Lot About Geratherm Medical (ETR:GME)
Jan 22
Consider This Before Buying Geratherm Medical AG (ETR:GME) For The 2.3% Dividend
Jan 04Update: Geratherm Medical (ETR:GME) Stock Gained 22% In The Last Year
Dec 17We Think Geratherm Medical (ETR:GME) Can Stay On Top Of Its Debt
Nov 29Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 19 | 1 | 2 | 3 | 1 |
| 12/31/2025 | 18 | 0 | 3 | 4 | 1 |
| 12/31/2024 | 18 | 0 | 4 | 5 | 1 |
| 6/30/2024 | 18 | -1 | -2 | 0 | N/A |
| 3/31/2024 | 20 | 0 | -1 | 1 | N/A |
| 12/31/2023 | 22 | 1 | 0 | 1 | N/A |
| 9/30/2023 | 24 | 1 | 1 | 2 | N/A |
| 6/30/2023 | 26 | 1 | 1 | 2 | N/A |
| 3/31/2023 | 26 | 1 | 1 | 3 | N/A |
| 12/31/2022 | 26 | 1 | 0 | 3 | N/A |
| 9/30/2022 | 25 | 0 | -1 | 2 | N/A |
| 6/30/2022 | 24 | 0 | 0 | 2 | N/A |
| 3/31/2022 | 24 | 0 | 0 | 1 | N/A |
| 12/31/2021 | 25 | 0 | 0 | 1 | N/A |
| 9/30/2021 | 27 | 2 | 1 | 2 | N/A |
| 6/30/2021 | 27 | 2 | 0 | 2 | N/A |
| 3/31/2021 | 29 | 2 | 0 | 3 | N/A |
| 12/31/2020 | 28 | 2 | 1 | 4 | N/A |
| 9/30/2020 | 25 | 1 | 0 | 3 | N/A |
| 6/30/2020 | 24 | 1 | 0 | 3 | N/A |
| 3/31/2020 | 20 | 0 | -1 | 2 | N/A |
| 12/31/2019 | 20 | 1 | -1 | 2 | N/A |
| 9/30/2019 | 22 | 1 | -2 | 2 | N/A |
| 6/30/2019 | 22 | 0 | -3 | 1 | N/A |
| 3/31/2019 | 23 | 1 | -3 | 2 | N/A |
| 12/31/2018 | 22 | 1 | -3 | 2 | N/A |
| 9/30/2018 | 21 | 1 | -2 | 2 | N/A |
| 6/30/2018 | 21 | 1 | 1 | 4 | N/A |
| 3/31/2018 | 20 | 1 | N/A | 3 | N/A |
| 12/31/2017 | 21 | 1 | N/A | 2 | N/A |
| 9/30/2017 | 22 | 2 | N/A | 2 | N/A |
| 6/30/2017 | 21 | 2 | N/A | 1 | N/A |
| 3/31/2017 | 22 | 3 | N/A | 1 | N/A |
| 12/31/2016 | 22 | 2 | N/A | 1 | N/A |
| 9/30/2016 | 22 | 2 | N/A | 2 | N/A |
| 6/30/2016 | 23 | 3 | N/A | 2 | N/A |
| 3/31/2016 | 22 | 2 | N/A | 3 | N/A |
| 12/31/2015 | 22 | 3 | N/A | 4 | N/A |
| 9/30/2015 | 21 | 2 | N/A | 3 | N/A |
| 6/30/2015 | 21 | 2 | N/A | 3 | N/A |
| 3/31/2015 | 20 | 2 | N/A | 2 | N/A |
| 12/31/2014 | 19 | 2 | N/A | 1 | N/A |
| 9/30/2014 | 18 | 2 | N/A | 1 | N/A |
| 6/30/2014 | 17 | 1 | N/A | 0 | N/A |
| 3/31/2014 | 16 | 1 | N/A | 1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GME is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).
Earnings vs Market: GME is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: GME is expected to become profitable in the next 3 years.
Revenue vs Market: GME's revenue (1.9% per year) is forecast to grow slower than the German market (5.4% per year).
High Growth Revenue: GME's revenue (1.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GME's Return on Equity is forecast to be low in 3 years time (1.8%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 06:31 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Geratherm Medical AG is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Oliver Wojahn | mwb research AG |
| IGOR KIM | Oddo Seydler |
| Enid Omerovic | Oddo Seydler |